Literature DB >> 16150940

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Lindsay M Morton1, Sophia S Wang, Susan S Devesa, Patricia Hartge, Dennis D Weisenburger, Martha S Linet.   

Abstract

Because the causes of most lymphoid neoplasms remain unknown, comparison of incidence patterns by disease subtype may provide critical clues for future etiologic investigations. We therefore conducted a comprehensive assessment of 114,548 lymphoid neoplasms diagnosed during 1992-2001 in 12 Surveillance, Epidemiology, and End Results (SEER) registries according to the internationally recognized World Health Organization (WHO) lymphoma classification introduced in 2001. Cases coded in International Classification of Diseases for Oncology, Second Edition (ICD-O-2), were converted to ICD-O-3 for WHO subtype assignment. Age-specific and age-adjusted rates were compared by sex and race (white, black, Asian). Age-adjusted trends in incidence were estimated by sex and race using weighted least squares log-linear regression. Diverse incidence patterns and trends were observed by lymphoid neoplasm subtype and population. In the elderly (75 years or older), rates of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma increased 1.4% and 1.8% per year, respectively, whereas rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year. Although whites bear the highest incidence burden for most lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predominance was observed for plasma cell and T-cell neoplasms. Asians have considerably lower rates than whites and blacks for CLL/SLL and Hodgkin lymphoma. We conclude that the striking differences in incidence patterns by histologic subtype strongly suggest that there is etiologic heterogeneity among lymphoid neoplasms and support the pursuit of epidemiologic analysis by subtype.

Entities:  

Mesh:

Year:  2005        PMID: 16150940      PMCID: PMC1895348          DOI: 10.1182/blood-2005-06-2508

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  80 in total

1.  The rise in incidence of lymphomas in Europe 1985-1992.

Authors:  R Cartwright; H Brincker; P M Carli; D Clayden; J W Coebergh; A Jack; R McNally; G Morgan; S de Sanjose; R Tumino; M Vornanen
Journal:  Eur J Cancer       Date:  1999-04       Impact factor: 9.162

Review 2.  Time trends in incidence of haematological malignancies and related conditions.

Authors:  R A Cartwright; E A Gilman; K A Gurney
Journal:  Br J Haematol       Date:  1999-08       Impact factor: 6.998

Review 3.  Focus on multiple myeloma.

Authors:  Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

4.  Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood.

Authors:  R Roosendaal; E J Kuipers; J Buitenwerf; C van Uffelen; S G Meuwissen; G J van Kamp; C M Vandenbroucke-Grauls
Journal:  Am J Gastroenterol       Date:  1997-09       Impact factor: 10.864

Review 5.  Epidemiology of the Revised European-American Lymphoma Classification subtypes.

Authors:  L J Herrinton
Journal:  Epidemiol Rev       Date:  1998       Impact factor: 6.222

6.  The increase of Hodgkin's disease incidence among young adults. Experience in Connecticut, 1935-1992.

Authors:  Y T Chen; T Zheng; M C Chou; P Boyle; T R Holford
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

7.  Cancer in children of nuclear industry employees: report on children aged under 25 years from nuclear industry family study.

Authors:  E Roman; P Doyle; N Maconochie; G Davies; P G Smith; V Beral
Journal:  BMJ       Date:  1999-05-29

Review 8.  Epidemiology and estimated population burden of selected autoimmune diseases in the United States.

Authors:  D L Jacobson; S J Gange; N R Rose; N M Graham
Journal:  Clin Immunol Immunopathol       Date:  1997-09

9.  Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States.

Authors:  M S Linet; L A Ries; M A Smith; R E Tarone; S S Devesa
Journal:  J Natl Cancer Inst       Date:  1999-06-16       Impact factor: 13.506

Review 10.  Mantle cell lymphoma.

Authors:  Francesco Bertoni; Emanuele Zucca; Franco Cavalli
Journal:  Curr Opin Hematol       Date:  2004-11       Impact factor: 3.284

View more
  486 in total

1.  Non-Hodgkin lymphoma in early life.

Authors:  Benjamin Emmanuel; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2012-05-22       Impact factor: 13.506

2.  Hodgkin lymphoma among US solid organ transplant recipients.

Authors:  Scott C Quinlan; Ola Landgren; Lindsay M Morton; Eric A Engels
Journal:  Transplantation       Date:  2010-11-15       Impact factor: 4.939

3.  Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.

Authors:  Andrei R Shustov; Theodore A Gooley; Brenda M Sandmaier; Judith Shizuru; Mohamed L Sorror; Firoozeh Sahebi; Peter McSweeney; Dietger Niederwieser; Benedetto Bruno; Rainer Storb; David G Maloney
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

4.  Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Authors:  Kenneth R Carson; Nancy L Bartlett; Jay R McDonald; Suhong Luo; Angelique Zeringue; Jingxia Liu; Qiang Fu; Su-Hsin Chang; Graham A Colditz
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

5.  Small intestinal cancer: a population-based study of incidence and survival patterns in the United States, 1992 to 2006.

Authors:  Osama Qubaiah; Susan S Devesa; Charles E Platz; Mark M Huycke; Graça M Dores
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

6.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Authors:  Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-15       Impact factor: 4.254

Review 7.  The Paracaspase MALT1.

Authors:  Janna Hachmann; Guy S Salvesen
Journal:  Biochimie       Date:  2015-09-16       Impact factor: 4.079

8.  Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.

Authors:  Hongxiu Li; Mark S Kaminski; Yifeng Li; Mehmet Yildiz; Peter Ouillette; Siân Jones; Heather Fox; Kathryn Jacobi; Kamlai Saiya-Cork; Dale Bixby; Daniel Lebovic; Diane Roulston; Kerby Shedden; Michael Sabel; Lawrence Marentette; Vincent Cimmino; Alfred E Chang; Sami N Malek
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

9.  Extremely rare case of primary esophageal mucous associated lymphoid tissue lymphoma.

Authors:  Ali Osama Malik; Zahid Baig; Aqeel Ahmed; Nasar Qureshi; Fatima Noor Malik
Journal:  World J Gastrointest Endosc       Date:  2013-09-16

10.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.